ClinicalTrials.gg

Program

reproxalap

Also written as “Reproxalap Ophthalmic Solution (0.25%)”, “Reproxalap Ophthalmic Solution (0.5%)” and “ADX-102 Ophthalmic Solution (0.5%)”.

Its studies are mostly in Dry Eye Syndromes · Conjunctivitis, Allergic · Alopecia Areata · Uveitis, Anterior, led by 2 companies.

Furthest: phase 3, since Apr 4, 201721 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aldeyra Therapeutics200 open or runningphase 3since Apr 4, 2017Dec 14, 2016none ahead
Aldena Therapeutics11 open or runningphase 2since Jan 22, 2025Jan 22, 2025Nov 2026phase 2 · NCT06826196

Also a collaborator on its studies: ORA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Dec 14, 2016.

  1. Oct 3, 2018Phase 2 study in Conjunctivitis, AllergicAldeyra Therapeutics · NCT03709121 · 70 enrolled · Canada
  2. Mar 15, 2019Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT03879863 · 422 enrolled · United States
  3. Dec 19, 2019Phase 3 study in Conjunctivitis, AllergicAldeyra Therapeutics · NCT04207736 · 95 enrolled · Canada
  4. Dec 14, 2020Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT04674358 · 329 enrolled · United States
  5. Jan 25, 2021Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT04735393 · 757 enrolled · United States
  6. Jul 12, 2021Phase 2 study in Dry Eye SyndromesAldeyra Therapeutics · NCT04971031 · 158 enrolled · United States
  7. Sep 13, 2021Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT05062330 · 361 enrolled · United States
  8. Oct 18, 2021Phase 2 study in Dry Eye SyndromesAldeyra Therapeutics · NCT05102409 · 56 enrolled · Canada
  9. Feb 1, 2022Phase 3 study in Conjunctivitis, AllergicAldeyra Therapeutics · NCT05234554 · 131 enrolled · Canada
  10. Jun 15, 2022Phase 2 study in Dry Eye SyndromesAldeyra Therapeutics · NCT05424549 · 63 enrolled · Canada
  11. Apr 25, 2024Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT06389214 · 132 enrolled · Canada
  12. May 17, 2024Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT06424444 · 421 enrolled · United States
  13. Jul 2, 2024Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT06493604 · 116 enrolled · United States
  14. Jan 22, 2025Aldena Therapeutics's first study: phase 2 study in Alopecia AreataNew to Aldena TherapeuticsAldena Therapeutics · NCT06826196 · 9 enrolled · United States, Canada

Ahead

  1. Nov 2026Primary completion: phase 2 study in Alopecia AreataAldena Therapeutics · NCT06826196

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06826196Alopecia Areata · United States, Canada2Active, not recruitingAldena TherapeuticsNov 20269
NCT06493604Dry Eye Syndromes · United States3CompletedAldeyra TherapeuticsFeb 27, 2025116
NCT06424444Dry Eye Syndromes · United States3CompletedAldeyra TherapeuticsNov 3, 2024421
NCT06389214Dry Eye Syndromes · Canada3CompletedAldeyra TherapeuticsJun 11, 2024132
NCT05424549Dry Eye Syndromes · Canada2CompletedAldeyra TherapeuticsMay 9, 202263
NCT05234554Conjunctivitis, Allergic · Canada3CompletedAldeyra TherapeuticsApr 22, 2023131
NCT05102409Dry Eye Syndromes · Canada2CompletedAldeyra TherapeuticsOct 25, 202156
NCT05062330Dry Eye Syndromes · United States3CompletedAldeyra TherapeuticsMar 4, 2022361
NCT04971031Dry Eye Syndromes · United States2CompletedAldeyra TherapeuticsSep 8, 2021158
NCT04735393Dry Eye Syndromes · United States3CompletedAldeyra TherapeuticsOct 11, 2022757
NCT04674358Dry Eye Syndromes · United States3CompletedAldeyra TherapeuticsSep 12, 2021329
NCT04207736Conjunctivitis, Allergic · Canada3CompletedAldeyra TherapeuticsFeb 16, 202195
NCT03879863Dry Eye Syndromes · United States3CompletedAldeyra TherapeuticsOct 4, 2019422
NCT03709121Conjunctivitis, Allergic · Canada2CompletedAldeyra TherapeuticsMar 20, 201970
NCT03660878Conjunctivitis, Allergic · United States2CompletedAldeyra TherapeuticsNov 19, 201952
NCT03494504Conjunctivitis, Allergic · United States3CompletedAldeyra TherapeuticsNov 5, 2018318
NCT03445650Sjogren-Larsson Syndrome · United States3CompletedAldeyra TherapeuticsJan 18, 202011
NCT03404115Dry Eye Syndromes · United States2CompletedAldeyra TherapeuticsJul 11, 2018300
NCT03162783Dry Eye Syndromes · United States2CompletedAldeyra TherapeuticsJul 6, 201751
NCT03131154Non-infectious Anterior Uveitis · United States3CompletedAldeyra TherapeuticsApr 19, 2019123
NCT03012165Conjunctivitis, Allergic · United States2CompletedAldeyra TherapeuticsMay 2017154

How it is read

Names in the registry

  • “Reproxalap Ophthalmic Solution (0.25%)”, 15 entries
  • “Reproxalap Ophthalmic Solution (0.5%)”, 3 entries
  • “ADX-102 Ophthalmic Solution (0.5%)”, 2 entries
  • “ALD-102 Solution”, 1 entry
  • “Reproxalap ophthalmic solution (0.25%)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
reproxalap (Aldeyra Therapeutics): development program | ClinicalTrials.gg